Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

61.55USD
8:39pm BST
Change (% chg)

$0.37 (+0.60%)
Prev Close
$61.18
Open
$61.24
Day's High
$61.91
Day's Low
$61.22
Volume
1,072,224
Avg. Vol
3,480,196
52-wk High
$66.41
52-wk Low
$52.83

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $176,050.70
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.91

Financials

  MRK.N Industry Sector
P/E (TTM): 35.16 30.95 32.74
EPS (TTM): 1.84 -- --
ROI: 6.58 14.84 14.38
ROE: 12.28 16.34 16.08

Novo's pioneering diabetes pill beats Victoza, Januvia in tests

COPENHAGEN Novo Nordisk's experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck & Co's Januvia and its own best-selling injectable treatment Victoza in tests.

21 Jun 2018

Novo's pioneering diabetes pill beats Victoza, Januvia in tests

COPENHAGEN, June 21 Novo Nordisk's experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck & Co's Januvia and its own best-selling injectable treatment Victoza in tests.

21 Jun 2018

Merck's Keytruda shows promise in treating advanced melanoma

Merck & Co Inc said on Monday long-term data from its cancer immunotherapy Keytruda showed promise in treating advanced melanoma patients, a day after announcing positive lung cancer data from the same treatment. | Video

04 Jun 2018

Merck's Keytruda shows promise in treating advanced melanoma

June 4 Merck & Co Inc said on Monday long-term data from its cancer immunotherapy Keytruda showed promise in treating advanced melanoma patients, a day after announcing positive lung cancer data from the same treatment.

04 Jun 2018

Merck's Keytruda extends lung cancer survival in two trials

CHICAGO Merck & Co's immunotherapy Keytruda improved survival as a stand-alone treatment for newly-diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer, new data released on Sunday showed, further cementing the company's lead in the most lucrative oncology market.

03 Jun 2018

UPDATE 1-Merck's Keytruda extends lung cancer survival in 2 trials

CHICAGO, June 3 Merck & Co's immunotherapy Keytruda improved survival as a stand-alone treatment for newly-diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer, new data released on Sunday showed, further cementing the company's lead in the most lucrative oncology market.

03 Jun 2018

EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

01 Jun 2018

REFILE-EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH, June 1 The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

01 Jun 2018

EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH, June 1 The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

01 Jun 2018

Roche, chasing Merck, notches another lung cancer win

ZURICH Roche's bid to keep Merck's cancer blockbuster Keytruda within striking distance got a lift on Tuesday when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients' survival.

29 May 2018

Competitors

Earnings vs. Estimates